Pila Pharma: Rights Issue Outcome

Research Note



Redeye leaves a short comment on Pila Pharma following the outcome of its rights issue which raised SEK6.9m before issuing costs.


Filip Einarsson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.